Results 121 to 130 of about 10,434 (181)

Medroxyprogesterone acetate in human serum

Journal of Steroid Biochemistry, 1981
Medroxyprogesterone acetate (MPA) exists in blood both in the unconjugated and in the conjugated state. The mean concentration of MPA obtained after enzymic hydrolysis of the conjugated fraction was 82% of that in the unconjugated fraction. The conjugate appears to be mainly a glucuronide since solvolysis released only small amounts of MPA. Metabolites
M, Mathrubutham, K, Fotherby
openaire   +2 more sources

Depot Medroxyprogesterone Acetate

2020
Depot medroxyprogesterone acetate (DMPA) is an injectable progestin-only contraceptive administered every 13 weeks. DMPA is an extremely effective contraceptive agent when used consistently. With typical use, approximately 6 out of 100 women will become pregnant in the first year of use, reflecting that some users do not return for repeat injections ...
Deanna C. McCullough, Kathryn M. Eraso, Andrew M. Kaunitz   +2 more
openaire   +1 more source

Medroxyprogesterone acetate therapy in hirsutism

British Journal of Dermatology, 1985
In a pilot study, 26 hirsute females were treated with medroxyprogesterone acetate (MPA). We used an ointment containing 0.2% MPA in 13 patients, subcutaneous injection of MPA into the hairy areas of the face in five patients and intramuscular injection of low doses of MPA in 13 patients, each for an average duration of 16 weeks.
J B, Schmidt, J, Huber, J, Spona
openaire   +2 more sources

Depot-medroxyprogesterone acetate: an update

Archives of Gynecology and Obstetrics, 2008
Depo-Provera is a contraceptive approved by the US Food and Drug Administration (FDA) since 1992 and used worldwide by more than 90 million women.Despite the fact that progestins are endogenous hormones that are secreted by the body, its excess might lead to detrimental health effects.
Sayed, Bakry, Zaher O, Merhi, Trudy J, Scalise, Mohamad S, Mahmoud, Ahmed, Fadiel, Frederick, Naftolin   +5 more
openaire   +2 more sources

A radioimmunoassay for serum medroxyprogesterone acetate

Journal of Steroid Biochemistry, 1978
Abstract A radioimmunoassay for measuring medroxyprogesterone acetate in serum or plasma is described using an antiserum produced against the steroid-3-carboxymethyloxime coupled to bovine serum albumin. The method has adequate accuracy, precision and sensitivity and the reliability criteria of the method are compared with those of other ...
K, Shrimanker, B N, Saxena, K, Fotherby
openaire   +2 more sources

Medroxyprogesterone Acetate (Depo-Provera)

Pediatrics, 1980
Members of the American Academy of Pediatrics have asked the Committee on Drugs to comment on the efficacy and the indications for use of the injectable progestin, medroxyprogesterone acetate (Depo-Provera), in adolescents. The Committee has reviewed the available data about the drug and assembled several possible indications for its use in adolescents.
Sydney Segal, Walter R. Anyan, Sanford N. Cohen, John Freeman, Reba M. Hill, Ralph E. Kauffman, Howard C. Mofenson, Albert W. Pruitt, Henry R. Shinefield   +8 more
openaire   +1 more source

Medroxyprogesterone Acetate and Sleep Apnea

Psychiatry and Clinical Neurosciences, 1987
Abstract: Seven patients with sleep apnea DOES and one with sleep apnea DIMS were treated with medroxyprogesterone acetate (MPA). The therapeutic effect was confirmed in most of them by polysomnographic recording. A marked increase of TST was observed in two patients whose AI and/or %SAT remarkably decreased.
openaire   +2 more sources

Toxicology of depot medroxyprogesterone acetate

Contraception, 1994
Depo-Provera (depot-medroxyprogesterone acetate or DMPA), administered either subcutaneously or intramuscularly, has undergone a thorough toxicological evaluation in a number of animal species. DMPA has been tested in short- and long-term toxicity studies in rodents, rabbits, and monkeys.
openaire   +2 more sources

Pharmacist-administered depot medroxyprogesterone acetate

Contraception, 2006
Continuation rates for women using depot medroxyprogesterone acetate (DMPA) for contraception in the United States are very low. Compliance/continuation rates at 3 months range from 57% to 71% with usual care and follow-up. At 6 months the range decreases to between 35% and 63%. The continuation rate at 1 year ranges from 23% to 45%.
openaire   +2 more sources

Glucocorticoid properties of medroxyprogesterone acetate

Life Sciences, 1972
Abstract In healthy young men, the maximum eosinopenic response to 40 mg oral medroxyprogesterone acetate (MPA) was about the same as to 20 mg oral hydrocortisone, though the rates of response were different. The hyperglycemic response to the MPA was also about the same as to the hydrocortisone, though the fasting glucose concentration rose faster ...
Michael Briggs, Maxine Briggs
openaire   +1 more source